Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Enzon 3Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Enzon 3Q

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Enzon

3Q Revenues: $49 million (+4%)

3Q Loss: $2.0 million (earnings were $87.5 million in 3Q07)

Comments: Total product sales were $28.9 million in the quarter (+16%) driven by Oncaspar sales, up 19% to $12.5 million. Contract manufacturing revenues were $5.3 million (+40%) due to growth from additional business and timing of shipments to customers. Royalty revenues were $14.6 million (-20%) as a result of the sold portion of Peg-Intron royalties. R&D expenses increased to $15.7 million (+49%) primarily due to $1.0 million in milestones related to the LNA platform program and the increase in costs associated with manufacturing process improvements and pharmaceutical properties of Oncaspar and Adagen.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters